Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed

Journal of Affective Disorders

Volumn 151, Issue 2, 2013, Pages 409-417

  Citrome, Leslie ^a   Goldberg, Joseph F ^b   Portland, Kimberly Blanchard ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Mylan Specialty LP   (United States)

Author keywords

Evidence based medicine; Major depressive disorder; Number needed to harm; Number needed to treat; Selegiline; Transdermal

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PLACEBO; QUETIAPINE; SELEGILINE; VILAZODONE;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; HUMAN; INJECTION SITE REACTION; INSOMNIA; MAJOR DEPRESSION; PRIORITY JOURNAL; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

EVIDENCE-BASED MEDICINE; MAJOR DEPRESSIVE DISORDER; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; SELEGILINE; TRANSDERMAL;

ADMINISTRATION, CUTANEOUS; ANTIDEPRESSIVE AGENTS; BIOMEDICAL RESEARCH; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELEGILINE;

EID: 84885481360     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.06.027     Document Type: Review

References (30)

1. J.D. Amsterdam A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder Journal of Clinical Psychiatry 64 2003 208 214
2. J.D. Amsterdam, and J.A. Bodkin Selegiline transdermal system in the prevention of relapse of major ressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial Journal of Clinical Psychopharmacology 26 2006 579 586
3. J.A. Bodkin, and J.D. Amsterdam Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients American Journal of Psychiatry 159 2002 1869 1875
4. L. Citrome Compelling or irrelevant? Using number needed to treat can help decide Acta Psychiatrica Scandinavica 117 2008 412 419
5. L. Citrome Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications Current Drug Safety 4 2009 229 237
6. L. Citrome Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed Postgraduate Medicine 122 4 2010 39 48
7. L. Citrome Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice 66 2012 356 368
8. L. Citrome, and J. Kantrowitz Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks Expert Review of Neurotherapeutics 8 2008 1079 1091
9. L. Citrome, and T.A. Ketter When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed International Journal of Clinical Practice 67 2013 407 411
10. A.H. Clayton, B.J. Campbell, A. Favit, Y. Yang, G. Moonsammy, C.M. Piontek, and J.D. Amsterdam Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale Journal of Clinical Psychiatry 68 2007 1860 1866
11. J. Cookson, I. Gilaberte, D. Desaiah, and D.K. Kajdasz Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat International Clinical Psychopharmacology 21 2006 267 273
12. A.D. Feiger, K. Rickels, M.A. Rynn, D.L. Zimbroff, and D.S. Robinson Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial Journal of Clinical Psychiatry 67 2006 1354 1361
13. H.C. Kraemer, and D.J. Kupfer Size of treatment effects and their importance to clinical research and practice Biological Psychiatry 59 2006 990 996
14. K.C. Lee, and J.J. Chen Transdermal selegiline for the treatment of major depressive disorder Neuropsychiatric Disease and Treatment 3 2007 527 537
15. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change British Journal of Psychiatry 134 1979 382 389
16. J.J. Nandagopal, and M.P. DelBello Selegiline transdermal system: a novel treatment option for major depressive disorder Expert Opinion on Pharmacotherapy 10 2009 1665 1673
17. C.B. Nemeroff The burden of severe depression: a review of diagnostic challenges and treatment alternatives Journal of Psychiatric Research 41 2007 189 206
18. C.U. Pae, J.A. Bodkin, K.B. Portland, M.E. Thase, and A.A. Patkar Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures Journal of Clinical Psychiatry 73 2012 661 668
19. C.U. Pae, H.K. Lim, C. Han, A. Neena, C. Lee, and A.A. Patkar Selegiline transdermal system: current awareness and promise Progress in Neuropsychopharmacology and Biological Psychiatry 31 2007 1153 1163
20. A.A. Patkar, K.B. Portland, and C.U. Pae Selegiline transdermal system in major depressive disorder Neuropsychiatry 2 2012 125 134
21. S.H. Preskorn Why the transdermal delivery of selegiline (6 mg/24 h) obviates the need for a dietary restriction on tyramine Journal of Psychiatric Practice 12 2006 168 172
22. D.S. Robinson, M.L. Gilmor, Y. Yang, G. Moonswammy, A.J. Azzaro, D.A. Oren, and B.J. Campbell Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials Psychopharmacology Bulletin 40 2007 15 28
23. D.S. Robinson, and J.D. Amsterdam The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability Journal of Affective Disorders 105 2008 15 23
24. Somerset Pharmaceuticals, Inc, 2000a. Clinical Study Report. A double-blind, placebo-controlled, parallel assessment of the safety and efficacy of the selegiline transdermal system in patients with major depression. Protocol S9303-E106-96B.
25. Somerset Pharmaceuticals, Inc.; 2000b. Clinical Study Report. A double-blind, placebo-controlled, parallel assessment of the safety and efficacy of the selegiline transdermal system in patients with major depression. Protocol S9303-P9804.
26. Somerset Pharmaceuticals, Inc.; 2000c. Clinical Study Report. A double-blind, placebo-controlled, parallel assessment of the safety and efficacy of the selegiline transdermal system in patients with major depression. Protocol S9303-E113-98B.
27. Somerset Pharmaceuticals, Inc.; 2000d. Clinical Study Report. A double-blind, placebo-controlled, parallel assessment of the safety and efficacy of two doses of the selegiline transdermal system (10 mg and 20 mg) in patients with major depression. Protocol S9303-E114.
28. Somerset Pharmaceuticals, Inc.; 2003. Clinical Study Report. A Phase III flexible dose titration study of the safety and efficacy of the selegiline transdermal system in patients with major depression. Protocol S9303-P0052.
29. Somerset Pharmaceuticals, Inc.; 2011. EMSAM (selegiline transdermal system). Product label. Revised August 2011. Available at: http://www.emsam.com/ assets/emsam/pdfs/pi.pdf. Accessed 1 February 2013.
30. US Food and Drug Administration, 2007. Emsam (Selegiline) Transdermal System Drug Approval Package. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2006/021336s000-021708s000TOC.cfm. (Accessed 31.01.13).